West Pharmaceutical Services (WST) Other Accumulated Expenses (2009 - 2026)

West Pharmaceutical Services has reported Other Accumulated Expenses for 18 years, with the latest figure at $171.1 million in Q2 2026.

• Quarterly Other Accumulated Expenses fell 23.2% year-over-year to $171.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $171.1 million (down 23.2% YoY) and the FY2025 annual result came in at $175.3 million, down 6.85% from the prior year.
• Other Accumulated Expenses retreated to $171.1 million in Q2 2026 per WST's latest filing, from $202.2 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $222.8 million in Q2 2025 and troughed at $136.5 million in Q3 2023.
• A 5-year average of $175.3 million and a median of $172.4 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses soared 33.77% in 2025, then retreated 23.2% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $183.8 million in 2022, then retreated by 15.56% to $155.2 million in 2023, then climbed by 21.26% to $188.2 million in 2024, then retreated by 6.85% to $175.3 million in 2025, then fell by 2.4% to $171.1 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $171.1 million, $202.2 million, and $175.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.